糖代谢紊乱对肝硬化相关并发症的影响

田彩云; 胡晗; 张国远; 林世德

doi:10.3969/j.issn.1001-5256.2021.05.046

糖代谢紊乱对肝硬化相关并发症的影响

DOI: 10.3969/j.issn.1001-5256.2021.05.046

遵义医科大学附属医院感染科，贵州遵义 563003

基金项目:

国家自然科学基金 (81860114)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：田彩云负责课题设计，资料分析，撰写论文；胡晗、张国远参与收集数据，修改论文；林世德负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
田彩云(1995—)，女，主要从事肝脏与糖代谢相关研究

通信作者:
林世德，linshide6@hotmail.com

中图分类号: R575.2
计量
- 文章访问数: 546
- HTML全文浏览量: 118
- PDF下载量: 55
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-06
- 录用日期: 2020-12-04
- 出版日期: 2021-05-20

Influence of glucose metabolism disorder on complications associated with liver cirrhosis

Department of Infectious Diseases, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, China

摘要

摘要: 糖尿病与肝硬化在全球范围内均有较高的发病率及死亡率，近十年国内外学者对两者的相关性作了大量研究。系统综述了近十年国内外在糖尿病对肝硬化及相关并发症影响方面的基础和临床研究进展，并对其可能的机制进行了总结。结果表明糖尿病可加速肝纤维化进程，增加肝硬化患者相关并发症及其进展为肝癌的风险，降低其生存率。
- 肝硬化 /
- 糖尿病 /
- 胰岛素抵抗
Abstract: Both diabetes mellitus and liver cirrhosis have high incidence rate and mortality rate around the world, and in recent ten years, scholars in China and globally have conducted many studies on the association between diabetes mellitus and liver cirrhosis. This article systematically reviews the advances in the basic and clinical research on the influence of diabetes mellitus on liver cirrhosis and its complications and summarizes possible mechanisms. The results show that diabetes mellitus can accelerate the process of liver fibrosis, increase the risk of complications and progression to liver cancer in patients with liver cirrhosis, and reduce their survival rate.
- Liver Cirrhosis /
- Diabetes Mellitus /
- Insulin Resistance

HTML全文

参考文献(51)

[1]	MOKDAD AA, LOPEZ AD, SHAHRAZ S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis[J]. BMC Med, 2014, 12: 145. DOI: 10.1186/s12916-014-0145-y.
[2]	ZHENG Y, LEY SH, HU FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018, 14(2): 88-98. DOI: 10.1038/nrendo.2017.151.
[3]	GARCÍA-COMPEÁN D, JÁQUEZ-QUINTANA JO, LAVALLE-GONZÁLEZ FJ, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study[J]. Ann Hepatol, 2012, 11(2): 240-248.
[4]	WILD SH, MORLING JR, MCALLISTER DA, et al. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases[J]. J Hepatol, 2016, 64(6): 1358-1364. DOI: 10.1016/j.jhep.2016.01.014.
[5]	KUMAR R. Hepatogenous diabetes: An underestimated problem of liver cirrhosis[J]. Indian J Endocrinol Metab, 2018, 22(4): 552-559. DOI: 10.4103/ijem.IJEM_79_18.
[6]	HAMED AE, ELSAHAR M, ELWAN NM, et al. Managing diabetes and liver disease association[J]. Arab J Gastroenterol, 2018, 19(4): 166-179. DOI: 10.1016/j.ajg.2018.08.003.
[7]	SAEED MJ, OLSEN MA, POWDERLY WG, et al. Diabetes mellitus is associated with higher risk of developing decompensated cirrhosis in chronic hepatitis C patients[J]. J Clin Gastroenterol, 2017, 51(1): 70-76. DOI: 10.1097/MCG.0000000000000566.
[8]	NISHIDA T, TSUJI S, TSUJⅡ M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis[J]. Am J Gastroenterol, 2006, 101(1): 70-75. DOI: 10.1111/j.1572-0241.2005.00307.x.
[9]	GARCÍA-COMPEÁN D, JÁQUEZ-QUINTANA JO, LAVALLE-GONZÁLEZ FJ, et al. Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis[J]. World J Gastroenterol, 2014, 20(22): 7011-7018. DOI: 10.3748/wjg.v20.i22.7011.
[10]	TROMBETTA M, SPIAZZI G, ZOPPINI G, et al. Review article: Type 2 diabetes and chronic liver disease in the Verona diabetes study[J]. Aliment Pharmacol Ther, 2005, 22 Suppl 2: 24-27. DOI: 10.1111/j.1365-2036.2005.02590.x.
[11]	HUANG YW, WANG TC, LIN SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: A nationwide cohort study[J]. Clin Infect Dis, 2013, 57(12): 1695-1702. DOI: 10.1093/cid/cit603.
[12]	DURAND F, VALLA D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD[J]. J Hepatol, 2005, 42(Suppl 1): s100-s107. DOI: 10.1016/j.jhep.2004.11.015.
[13]	WONG GL, CHAN HL, YU Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations[J]. Aliment Pharmacol Ther, 2014, 39(8): 883-893. DOI: 10.1111/apt.12658.
[14]	MCPHERSON S, HARDY T, HENDERSON E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management[J]. J Hepatol, 2015, 62(5): 1148-1155. DOI: 10.1016/j.jhep.2014.11.034.
[15]	HUANG YW, YANG SS, FU SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study[J]. Hepatology, 2014, 60(3): 807-814. DOI: 10.1002/hep.27212.
[16]	ELKRIEF L, RAUTOU PE, SARIN S, et al. Diabetes mellitus in patients with cirrhosis: Clinical implications and management[J]. Liver Int, 2016, 36(7): 936-948. DOI: 10.1111/liv.13115.
[17]	PARADIS V, PERLEMUTER G, BONVOUST F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis[J]. Hepatology, 2001, 34(4 Pt 1): 738-744. DOI: 10.1053/jhep.2001.28055.
[18]	FEHRENBACH H, WEISKIRCHEN R, KASPER M, et al. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts[J]. Hepatology, 2001, 34(5): 943-952. DOI: 10.1053/jhep.2001.28788.
[19]	PETTA S, CAMMÀ C, DI MARCO V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection[J]. Am J Gastroenterol, 2008, 103(5): 1136-1144. DOI: 10.1111/j.1572-0241.2008.01813.x.
[20]	WOOD MJ, POWELL LW, DIXON JL, et al. Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: The role of diabetes mellitus[J]. Hepatology, 2012, 56(3): 904-911. DOI: 10.1002/hep.25720.
[21]	JEON HK, KIM MY, BAIK SK, et al. Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage[J]. Dig Dis Sci, 2013, 58(11): 3335-3341. DOI: 10.1007/s10620-013-2802-y.
[22]	QI X, PENG Y, LI H, et al. Diabetes is associated with an increased risk of in-hospital mortality in liver cirrhosis with acute upper gastrointestinal bleeding[J]. Eur J Gastroenterol Hepatol, 2015, 27(4): 476-477. DOI: 10.1097/MEG.0000000000000324.
[23]	CAMMÀ C, PETTA S, di MARCO V, et al. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis[J]. Hepatology, 2009, 49(1): 195-203. DOI: 10.1002/hep.22655.
[24]	YANG CH, CHIU YC, CHEN CH, et al. Diabetes mellitus is associated with gastroesophageal variceal bleeding in cirrhotic patients[J]. Kaohsiung J Med Sci, 2014, 30(10): 515-520. DOI: 10.1016/j.kjms.2014.06.002.
[25]	MUNIYAPPA R, QUON MJ. Insulin action and insulin resistance in vascular endothelium[J]. Curr Opin Clin Nutr Metab Care, 2007, 10(4): 523-530. DOI: 10.1097/MCO.0b013e32819f8ecd.
[26]	PUGLIESE D, LEE SS, KOSHY A, et al. Systemic and splanchnic hemodynamic effects of intravenous hypertonic glucose in patients with cirrhosis[J]. Hepatology, 1988, 8(3): 643-646. DOI: 10.1002/hep.1840080334.
[27]	ARAB JP, MARTIN-MATEOS RM, SHAH VH. Gut-liver axis, cirrhosis and portal hypertension: The chicken and the egg[J]. Hepatol Int, 2018, 12(Suppl 1): 24-33. DOI: 10.1007/s12072-017-9798-x.
[28]	BUTT Z, JADOON NA, SALARIA ON, et al. Diabetes mellitus and decompensated cirrhosis: Risk of hepatic encephalopathy in different age groups[J]. J Diabetes, 2013, 5(4): 449-455. DOI: 10.1111/1753-0407.12067.
[29]	SIGAL SH, STANCA CM, KONTORINIS N, et al. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis[J]. Am J Gastroenterol, 2006, 101(7): 1490-1496. DOI: 10.1111/j.1572-0241.2006.00649.x.
[30]	JEPSEN P, WATSON H, ANDERSEN PK, et al. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients[J]. J Hepatol, 2015, 63(5): 1133-1138. DOI: 10.1016/j.jhep.2015.07.007.
[31]	RAFF EJ, KAKATI D, BLOOMER JR, et al. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases[J]. J Clin Transl Hepatol, 2015, 3(1): 9-16. DOI: 10.14218/JCTH.2015.00001.
[32]	AMPUERO J, RANCHAL I, DEL MAR DÍAZ-HERRERO M, et al. Role of diabetes mellitus on hepatic encephalopathy[J]. Metab Brain Dis, 2013, 28(2): 277-279. DOI: 10.1007/s11011-012-9354-2.
[33]	STURGEON JP, SHAWCROSS DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments[J]. Expert Rev Gastroenterol Hepatol, 2014, 8(1): 83-100. DOI: 10.1586/17474124.2014.858598.
[34]	Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications[J]. Clin Mol Hepatol, 2018, 24(3): 230-277. DOI: 10.3350/cmh.2018.1005.
[35]	ELKRIEF L, CHOUINARD P, BENDERSKY N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C[J]. Hepatology, 2014, 60(3): 823-831. DOI: 10.1002/hep.27228.
[36]	MOREAU R, DELÈGUE P, PESSIONE F, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites[J]. Liver Int, 2004, 24(5): 457-464. DOI: 10.1111/j.1478-3231.2004.0991.x.
[37]	BALAKRISHNAN M, GARCIA-TSAO G, DENG Y, et al. Hepatic arteriolosclerosis: A small-vessel complication of diabetes and hypertension[J]. Am J Surg Pathol, 2015, 39(7): 1000-1009. DOI: 10.1097/PAS.0000000000000419.
[38]	SIMONETTO DA, PICCOLO SERAFIM L, GALLO de MORAES A, et al. Management of sepsis in patients with cirrhosis: Current evidence and practical approach[J]. Hepatology, 2019, 70(1): 418-428. DOI: 10.1002/hep.30412.
[39]	MULLER LM, GORTER KJ, HAK E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus[J]. Clin Infect Dis, 2005, 41(3): 281-288. DOI: 10.1086/431587.
[40]	DIAZ J, MONGE E, ROMAN R, et al. Diabetes as a risk factor for infections in cirrhosis[J]. Am J Gastroenterol, 2008, 103(1): 248. DOI: 10.1111/j.1572-0241.2007.01562_9.x.
[41]	SHIVASWAMY V, BOERNER B, LARSEN J. Post-transplant diabetes mellitus: Causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
[42]	LI Q, LI WW, YANG X, et al. Type 2 diabetes and hepatocellular carcinoma: A case-control study in patients with chronic hepatitis B[J]. Int J Cancer, 2012, 131(5): 1197-1202. DOI: 10.1002/ijc.27337.
[43]	ZHENG Z, ZHANG C, YAN J, et al. Diabetes mellitus is associated with hepatocellular carcinoma: A retrospective case-control study in hepatitis endemic area[J]. PLoS One, 2013, 8(12): e84776. DOI: 10.1371/journal.pone.0084776.
[44]	KOH WP, WANG R, JIN A, et al. Diabetes mellitus and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study[J]. Br J Cancer, 2013, 108(5): 1182-1188. DOI: 10.1038/bjc.2013.25.
[45]	LIN CC, CHIANG JH, LI CI, et al. Cancer risks among patients with type 2 diabetes: A 10-year follow-up study of a nationwide population-based cohort in Taiwan[J]. BMC Cancer, 2014, 14: 381. DOI: 10.1186/1471-2407-14-381.
[46]	DYAL HK, AGUILAR M, BARTOS G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: A systematic review[J]. Dig Dis Sci, 2016, 61(2): 636-645. DOI: 10.1007/s10620-015-3983-3.
[47]	LI X, XU H, GAO P. Diabetes mellitus is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection in China[J]. Med Sci Monit, 2018, 24: 6729-6734. DOI: 10.12659/MSM.911702.
[48]	CHEN CL, YANG HI, YANG WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan[J]. Gastroenterology, 2008, 135(1): 111-121. DOI: 10.1053/j.gastro.2008.03.073.
[49]	PANG Y, KARTSONAKI C, TURNBULL I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: A prospective study of 0.5 million people[J]. Hepatology, 2018, 68(4): 1308-1318. DOI: 10.1002/hep.30083.
[50]	HSIANG JC, GANE EJ, BAI WW, et al. Type 2 diabetes: A risk factor for liver mortality and complications in hepatitis B cirrhosis patients[J]. J Gastroenterol Hepatol, 2015, 30(3): 591-599. DOI: 10.1111/jgh.12790.
[51]	HAYASHI T, OGAWA E, FURUSYO N, et al. Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C[J]. Infect Agent Cancer, 2016, 11: 9. DOI: 10.1186/s13027-016-0056-y.